Study of a new drug combination to treat Leukemia

Registry ID

EUCTR2008-004932-19

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2009-02-11

Completion date

2018-05-17

Last update

2026-08-16

Conditions

• Chronic Lymphocytic Leukaemia
• Leucemia Linfocítica Crónica

Summary

The primary objective is to evaluate progression-free-survival of ofatumumab added to chlorambucil therapy vs. chlorambucil therapy for the treatment of previously untreated (frontline) CLL.

Locations

• , , Ireland
• , , Belgium
• , , Germany
• , , Sweden
• , , Greece
• , , Spain
• , , Czechia
• , , Italy
• , , France
• , , Netherlands
• , , UK

Related clinical trials

• Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
• A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
• Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
• Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

View on source registry